224 related articles for article (PubMed ID: 24628417)
1. Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.
Erdélyi LS; Balla A; Patócs A; Tóth M; Várnai P; Hunyady L
Mol Endocrinol; 2014 May; 28(5):634-43. PubMed ID: 24628417
[TBL] [Abstract][Full Text] [Related]
2. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
[TBL] [Abstract][Full Text] [Related]
3. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
Robben JH; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
[TBL] [Abstract][Full Text] [Related]
4. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
Ranadive SA; Ersoy B; Favre H; Cheung CC; Rosenthal SM; Miller WL; Vaisse C
Clin Endocrinol (Oxf); 2009 Sep; 71(3):388-93. PubMed ID: 19170711
[TBL] [Abstract][Full Text] [Related]
5. Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V).
Armstrong SP; Seeber RM; Ayoub MA; Feldman BJ; Pfleger KD
PLoS One; 2013; 8(6):e65885. PubMed ID: 23762448
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.
Rochdi MD; Vargas GA; Carpentier E; Oligny-Longpré G; Chen S; Kovoor A; Gitelman SE; Rosenthal SM; von Zastrow M; Bouvier M
Mol Pharmacol; 2010 May; 77(5):836-45. PubMed ID: 20159941
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
[TBL] [Abstract][Full Text] [Related]
8. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Robben JH; Sze M; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
[TBL] [Abstract][Full Text] [Related]
9. Lack of responsiveness to 1-desamino-D arginin vasopressin (desmopressin) in male patients with nephrogenic syndrome of inappropriate antidiuresis: from bench to bedside.
Vandergheynst F; Pradier O; Beukinga I; Kornreich A; Vassart G; Decaux G
Eur J Clin Invest; 2012 Mar; 42(3):254-9. PubMed ID: 21834801
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of a loss-of-function mutant I324M of arginine vasopressin receptor 2 in X-linked nephrogenic diabetes insipidus.
Wang L; Guo W; Fang C; Feng W; Huang Y; Zhang X; Liu M; Cui J
Sci Rep; 2021 May; 11(1):11057. PubMed ID: 34040143
[TBL] [Abstract][Full Text] [Related]
11. A case of a novel mutant vasopressin receptor-dependent nephrogenic diabetes insipidus with bilateral non-obstructive hydronephrosis in a middle aged man: differentiation from aquaporin-dependent nephrogenic diabetes insipidus by response of factor VII and von Willebrand factor to 1-diamino-8-arginine vasopressin administration.
Miyakoshi M; Kamoi K; Uchida S; Sasaki S
Endocr J; 2003 Dec; 50(6):809-14. PubMed ID: 14709855
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potentials of nonpeptidic V2R agonists for partial cNDI-causing V2R mutants.
Kuramoto R; Kise R; Kanno M; Kawakami K; Ikuta T; Makita N; Inoue A
PLoS One; 2024; 19(5):e0303507. PubMed ID: 38748623
[TBL] [Abstract][Full Text] [Related]
13. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
Los EL; Deen PM; Robben JH
J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
[TBL] [Abstract][Full Text] [Related]
14. Biochemical basis of partial nephrogenic diabetes insipidus phenotypes.
Sadeghi H; Robertson GL; Bichet DG; Innamorati G; Birnbaumer M
Mol Endocrinol; 1997 Nov; 11(12):1806-13. PubMed ID: 9369448
[TBL] [Abstract][Full Text] [Related]
15. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
Robben JH; Kortenoeven ML; Sze M; Yae C; Milligan G; Oorschot VM; Klumperman J; Knoers NV; Deen PM
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12195-200. PubMed ID: 19587238
[TBL] [Abstract][Full Text] [Related]
16. A low-affinity vasopressin V2-receptor gene in a kindred with X-linked nephrogenic diabetes insipidus.
Yokoyama K; Yamauchi A; Izumi M; Itoh T; Ando A; Imai E; Kamada T; Ueda N
J Am Soc Nephrol; 1996 Mar; 7(3):410-4. PubMed ID: 8704106
[TBL] [Abstract][Full Text] [Related]
17. Functional Rescue of a Nephrogenic Diabetes Insipidus Causing Mutation in the V2 Vasopressin Receptor by Specific Antagonist and Agonist Pharmacochaperones.
Szalai L; Sziráki A; Erdélyi LS; Kovács KB; Tóth M; Tóth AD; Turu G; Bonnet D; Mouillac B; Hunyady L; Balla A
Front Pharmacol; 2022; 13():811836. PubMed ID: 35153784
[TBL] [Abstract][Full Text] [Related]
18. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
Prosperi F; Suzumoto Y; Marzuillo P; Costanzo V; Jelen S; Iervolino A; Guarino S; La Manna A; Miraglia Del Giudice E; Perna AF; Zacchia M; Cordat E; Capasso G; Trepiccione F
Sci Rep; 2020 Oct; 10(1):16383. PubMed ID: 33009446
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
[TBL] [Abstract][Full Text] [Related]
20. An X-linked NDI mutation reveals a requirement for cell surface V2R expression.
Sadeghi HM; Innamorati G; Birnbaumer M
Mol Endocrinol; 1997 Jun; 11(6):706-13. PubMed ID: 9171234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
